688117 ChengDu Sheng Nuo Biotec
- 28.55
- +0.33+1.17%
ChengDu Sheng Nuo Biotec News
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Shengnuo Biology (688117): Rapid growth in Q3 performance, substantial order landing to boost medium and long-term development.
Q3 performance grew rapidly, with the three core sub-businesses showing overall stable development in 2024 Q1-3. The company achieved revenue of 0.338 billion yuan, a year-on-year increase of 16.00%; net income attributable to shareholders was 56.95 million yuan, a year-on-year increase of 63.66.
Shengnuo Biology (688117): A pioneer in the peptide field, overseas layout to create long-term growth space.
The company released the Q3 financial report for 2024, with a revenue of 0.139 billion yuan, an increase of 18.32% year-on-year, and a net income attributable to non-controlling interests of 34.53 million yuan, an increase of 144.80% year-on-year. Revenue for the first three quarters of 2024 reached 3 billion yuan.
Shengnuo Biotech: Third Quarter Report 2024
Third Quarter Report 2024
ChengDu ShengNuo Biotec's Nine-Month Profit Seen to Surge Up to 76%
VOLUNTARY DISCLOSURE ANNOUNCEMENT FOR THE FIRST THREE QUARTERS OF 2024
Another one! Peptide products drive 'hot' performance, Sanuo Biological's net profit for the first three quarters is expected to increase by 76%.
①Peptide active pharmaceutical ingredients and formulation products are selling well, driving Shen Nuo Biotech's net income in the first three quarters to reach as high as 61.1987 million yuan, with the highest year-on-year increase of 75.88%. ②In September of this year, Shen Nuo Biotech signed a GLP-1 peptide active pharmaceutical ingredient supply contract worth up to 0.35 billion yuan, with a performance period until December 31, 2025.
Express News | Shengnuo Biotechnology: It is expected that the net income in the first three quarters will increase by 43.90% to 75.88% year-on-year.
Express News | Shengnuo Biotechnology: There is still uncertainty whether the trade can be finally completed.
Shengnuo Biotechnology (688117): Capacity expansion in the pipeline, poised for rapid development. Peptide drugs are experiencing rapid growth.
Recommendation logic: 1) In 2024, global peptide drug sales reached $87.6 billion, GLP-1 drugs are booming, and it is expected that by 2030, china's peptide active pharmaceutical ingredient market size will reach 65.25 billion yuan; 2) Company's production capacity landed.
Express News | Star market closing: SSE Science and Technology Innovation Board 50 Index fell by 0.48%, medical instruments and biopharmaceutical sectors declined.
Stock market volatility | With the brokerage's positive outlook, Shengnuo Biotechnology rose more than 9% in the afternoon.
Gelonghui on September 19th: Yesterday, Sanuo Biotech (688117.SH), which fell more than 9%, surged to over 9% in the afternoon, and is now trading at 29.7 yuan, with a total market value of 3.33 billion yuan. The latest report from China Post Securities points out that the company has frequent bullish news, and its medium to long-term development is positive. The climbing production capacity of the company's GLP-1 active pharmaceutical ingredient, combined with the release of substantial orders, is expected to contribute substantial performance. In early September, the company proposed to invest 30 million yuan to subscribe for 22.78% equity of the target company in Tanzania, which is beneficial for further expanding the international layout of the company's peptide products. Maintain the recommendation and give a “buy” rating.
San Nuo Biology (688117): The new signed orders are expected to significantly increase the company's performance, and the long-term development continues to improve.
Event: On September 17th, Sanuo Biotech released an announcement on the signing of a significant contract for daily operations by its wholly-owned subsidiary. Sanuo Pharmaceutical, a wholly-owned subsidiary of the company, recently signed a Product Purchase Contract with a certain client to supply the contract party.
Express News | Star Market Market Summary: Biopharmaceuticals and lithium battery sectors performed poorly, while semiconductor sector had mixed gains and losses.
ChengDu ShengNuo Biotec Unit Signs Up to 350 Million-Yuan Peptide Supply Contract
Sanon Bio (688117.SH): Subsidiary signs GLP-1 peptide active pharmaceutical ingredient sales contract not exceeding 0.35 billion yuan
Shengnuo Biotech (688117.SH) announced that Chengdu Shengnuo Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (“Shengnuo...
Express News | Shengnuo Biology: Wholly-owned subsidiary signs significant contract for daily operation.
Shengnuo Biology (688117): Deeply cultivating the peptide industry chain business is steadily growing, and the GLP-1 peptide active pharmaceutical ingredient continues to be released.
On July 31st, the company released its interim report for 2024, with revenue of 0.199 billion yuan (+14.4%) and net income attributable to shareholders of 0.022 billion yuan (+8.1%), with a non-recurring net income attributable to shareholders.
Shengnuo Biology (688117.SH) plans to invest 30 million yuan to subscribe for a 22.78% equity stake in Africa Bio Chem Co.Ltd, expanding the overseas market size for peptide products.
Shengnuo Biology (688117.SH) announced that the company plans to contribute 30 million yuan RMB to subscribe to East Africa Tanzania...
Analysis
Price Target
No Data
No Data